AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - AnaptysBio, Inc. reported a quarterly loss of $1.14 per share, which was better than the Zacks Consensus Estimate of a loss of$1.72, representing an earnings surprise of 33.72% [1] - The company achieved revenues of $30.02 million for the quarter ended September 2024, significantly surpassing the Zacks Consensus Estimate by 279.19$3.32 million a year ago [2] - AnaptysBio shares have underperformed the market, losing about 6.9% since the beginning of the year, while the S&P 500 gained 19.8% [3] Financial Performance - Over the last four quarters, AnaptysBio has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$1.74 on revenues of$8.11 million, and for the current fiscal year, it is -$6.84 on revenues of$31.89 million [7] Industry Context - AnaptysBio operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 38% of over 250 Zacks industries [8] - The industry’s performance can significantly impact AnaptysBio's stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of AnaptysBio's stock price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for AnaptysBio is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]